Biochimica Et Biophysica Acta-molecular Basis Of Disease

Journal Title：Biochimica Et Biophysica Acta-molecular Basis Of Disease

BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. The submission of uninvited reviews to BBA - Molecular Basis of Disease is strongly discouraged, and any such uninvited review should be accompanied by a coverletter outlining the compelling reasons why the review should be considered.

BBA 疾病的分子基礎 (BBA Molecular Basis of Disease) 致力于解決疾病過程和人類疾病模型的生物化學和分子遺傳學問題。該期刊涵蓋衰老、癌癥、代謝、神經(jīng)和免疫疾病等方面的內(nèi)容。特別鼓勵投稿專注于使用動物模型闡明每種疾病的生化和機制見解。稿件應強調(diào)疾病途徑的潛在機制，并為理解和/或治療這些疾病提供新穎的貢獻。高度描述性和方法開發(fā)性投稿可能會在未經(jīng)全面審查的情況下被拒絕。強烈反對向 BBA - 疾病的分子基礎 (BBA - Molecular Basis of Disease) 提交未經(jīng)邀請的評論，任何此類未經(jīng)邀請的評論都應附上一封求職信，概述應考慮該評論的令人信服的理由。

Biochimica Et Biophysica Acta-molecular Basis Of Disease創(chuàng)刊于1947年，由Elsevier出版商出版，收稿方向涵蓋生物 - 生化與分子生物學全領域，此刊是該細分領域中屬于非常不錯的SCI期刊，在行業(yè)細分領域中學術影響力較大，專業(yè)度認可很高，所以對原創(chuàng)文章要求創(chuàng)新性較高，如果您的文章質(zhì)量很高，可以嘗試。平均審稿速度 一般,3-6周 約8.8周，影響因子指數(shù)4.2，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。